USA Health has a new tool in its arsenal to treat liver tumors. As FOX 10’s Lee Peck shows us -- the groundbreaking therapy is not only non-invasive but is an outpatient procedure.

PURPOSEGEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus gemcitabine alone as second-line treatment ...

Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early ...

"PanTher Therapeutics launches second trial for chemotherapy patch" was originally created and published by Clinical Trials ...

Earlier diagnoses and advancements in treatment options are providing hope for patients with endometrial cancer like Yaca.

Paclitaxel (PTX) has emerged as one of the first-line drug candidates in cancer therapy due to its potency and profound anticancer potential. Derived from a rich natural source, it stands out as a ...

A noninvasive ultrasound treatment that destroys liver tumours without surgery or radiation will soon be offered on the NHS in Cambridge in a European first.

Scientists at UC San Francisco have discovered how pancreatic cancer cells thrive in the lungs or liver, environments that are as distinct to cells as the ocean and desert are to animals. The spread ...

Liver cancer is a lethal disease with limited treatment options for advanced stages. While risk factors such as viral hepatitis, alcohol use, and obesity increase the likelihood of hepatocellular ...

A randomized phase 2 study of a GSK-3ß inhibitor plus gemcitabine/nab-paclitaxel showed survival benefit in patients with untreated metastatic pancreatic ductal ...

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

The study marks the first investigation into the long-term outcomes for patients with locally advanced liver cancer receiving this treatment.